Actively Recruiting
Evaluating the Pharmacokinetics and Safety of Oral Etavopivat in Children With Sickle Cell Disease in an Open-Label Study
Led by Forma Therapeutics, Inc. · Updated on 2026-09-18
95
Participants Needed
18
Research Sites
76 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.
CONDITIONS
Brief Title
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here